Shandong Xinhua Pharmaceutical Company Limited (XIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€56.11 Million ≈ $65.60 Million USD) by net assets (€4.70 Billion ≈ $5.50 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XIN net asset quality score to measure how much of total assets are equity-financed.
Shandong Xinhua Pharmaceutical Company Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Shandong Xinhua Pharmaceutical Company L to evaluate the quality of earnings relative to operating cash generation.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Xinhua Pharmaceutical Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dollar Industries Limited
NSE:DOLLAR
|
0.049x |
|
Mieco Chipboard Bhd
KLSE:5001
|
0.017x |
|
Changsha Kaiyuan Instruments
SHE:300338
|
2.512x |
|
NoHo Partners Oyj
HE:NOHO
|
0.117x |
|
E-Life Mall Corp
TW:6281
|
0.110x |
|
PERENNIAL ENERGY HD-01
F:PEZ
|
N/A |
|
Som Distilleries & Breweries Limited
NSE:SDBL
|
0.110x |
|
FutureFuel Corp
NYSE:FF
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Shandong Xinhua Pharmaceutical Company L (XIN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €5.46 Billion ≈ $6.38 Billion |
€533.73 Million ≈ $623.98 Million |
0.098x | +38.85% |
| 2024-12-31 | €5.22 Billion ≈ $6.10 Billion |
€367.61 Million ≈ $429.78 Million |
0.070x | +26.84% |
| 2023-12-31 | €4.78 Billion ≈ $5.58 Billion |
€265.28 Million ≈ $310.14 Million |
0.056x | -68.13% |
| 2022-12-31 | €4.35 Billion ≈ $5.09 Billion |
€758.24 Million ≈ $886.46 Million |
0.174x | +145.62% |
| 2021-12-31 | €3.65 Billion ≈ $4.27 Billion |
€259.12 Million ≈ $302.93 Million |
0.071x | -42.72% |
| 2020-12-31 | €3.39 Billion ≈ $3.96 Billion |
€420.19 Million ≈ $491.24 Million |
0.124x | +10.66% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
€348.27 Million ≈ $407.17 Million |
0.112x | -3.33% |
| 2018-12-31 | €2.80 Billion ≈ $3.27 Billion |
€323.91 Million ≈ $378.68 Million |
0.116x | -23.39% |
| 2017-12-31 | €2.58 Billion ≈ $3.02 Billion |
€389.97 Million ≈ $455.92 Million |
0.151x | -28.45% |
| 2016-12-31 | €2.08 Billion ≈ $2.43 Billion |
€439.35 Million ≈ $513.64 Million |
0.211x | +20.25% |
| 2015-12-31 | €1.98 Billion ≈ $2.32 Billion |
€348.64 Million ≈ $407.59 Million |
0.176x | -3.00% |
| 2014-12-31 | €1.91 Billion ≈ $2.24 Billion |
€346.34 Million ≈ $404.91 Million |
0.181x | +224.96% |
| 2013-12-31 | €1.88 Billion ≈ $2.20 Billion |
€104.99 Million ≈ $122.75 Million |
0.056x | -- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more